Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00772005 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Efficacy and Safety of Armodafinil as Adjunctive Therapy in Adults With Schizophrenia
A Phase 2 study of Schizophrenia, sponsored by Cephalon.
- Completed
- Registry status
- Phase 2
- Development phase
- 287
- Enrollment target
- 20
- Study locations
NCT00772005 is a Phase 2 study of Schizophrenia that has completed, run by Cephalon. The registered enrollment target is 287 participants, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (32% higher). The trial reports 20 study locations across 7 states.
The verdict
NCT00772005, a Phase 2 study of Schizophrenia, has completed, sponsored by Cephalon.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 287 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of the study is to evaluate whether armodafinil treatment is more effective than placebo as adjunctive therapy to antipsychotic medication in alleviating the negative symptoms of schizophrenia
Conditions Studied
Interventions
- DRUG placebo
- DRUG armodafinil
Study Locations (20)
California
- Omega Clinical Trials - Anaheim
- Synergy Clinical Research Center - Escondido
- Collaborative NeuroScience - Garden Grove
- Excell Research - Oceanside
- CNRI Los Angeles LLC - Pico Rivera
- CNRI-San Diego LLC - San Diego
- Neuropsychiatric Research Center of Orange County - Santa Ana
- Collaborative NeuroScience Network - Torrance
Florida
- Scientific Clinical Research, Inc. - Aventura
- Mental Health Advocates. Inc - Boca Raton
- Fidelity Clinical Research - Lauderhill
- Stedman Clinical Trials, LLC - Tampa
Georgia
- Atlanta Center for Medical Research - Atlanta
- Comprehensive Neuroscience Inc - Atlanta
- Carman Research - Smyrna
Connecticut
- The Hospital of Central Connecticut - New Britain
- Yale University School of Medicine - New Haven
Arkansas
- K and S Professional Research Services, LLC - Little Rock
Illinois
- Uptown Research Institute. LLC - Chicago
Kansas
- Via Christi Research - Wichita
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 287 participants |
| Start Date | 2008-09 |
| Est. Completion | 2010-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00772005
The ClinicalTrials.gov registry entry for NCT00772005 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 287 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (32% higher). The listed sponsor is Cephalon, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00772005 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT00772005 about?
NCT00772005 is a clinical study titled "Study to Evaluate the Efficacy and Safety of Armodafinil as Adjunctive Therapy in Adults With Schizophrenia". The primary objective of the study is to evaluate whether armodafinil treatment is more effective than placebo as adjunctive therapy to antipsychotic medication in alleviating the negative symptoms of schizophrenia
What is the current status of trial NCT00772005?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 287 participants. The study started on 2008-09. Estimated completion is 2010-05.
What conditions does trial NCT00772005 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT00772005?
The interventions under investigation include: placebo (DRUG), armodafinil (DRUG).
Who is sponsoring clinical trial NCT00772005?
This trial is sponsored by Cephalon, which has 64 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00772005 being conducted?
This trial has 20 study locations across Arkansas, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
RECRUITING · Phase 2
-
Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
RECRUITING · Phase 2
-
A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
RECRUITING · Phase 2
-
Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia
RECRUITING · Phase 2
-
Study of ALTO-101 in Patients With Schizophrenia
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.